BRIEF-Allakos Says AK006 Well-Tolerated In Ongoing Phase 1 Trial

Reuters06-26

June 25 (Reuters) - Allakos Inc :

* ALLAKOS ANNOUNCES POSITIVE RESULTS FROM ITS ONGOING PHASE 1 TRIAL OF AK006 IN HEALTHY VOLUNTEERS, WITH AK006 DEMONSTRATING HIGH RECEPTOR OCCUPANCY ON MAST CELLS AND A FAVORABLE SAFETY PROFILE

* ALLAKOS INC: AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE

* ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE -

* ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE

* ALLAKOS INC - AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH LEVELS DEMONSTRATING INHIBITORY ACTIVITY IN PRECLINICAL EXPERIMENTS

* ALLAKOS INC - AK006 SHOWED DOSE LINEAR EXPOSURE AND WITH AN ESTIMATED HALF-LIFE OF 21 DAYS FOR 720 MG IV DOSE

* ALLAKOS- IN PHASE 1 STUDY RESULTS AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH THOSE SHOWING MAST CELL INHIBITION IN PRECLINICAL EXPERIMENTS

Source text for Eikon: Further company coverage:

((reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446187991?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-26 04:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446187991","market":"us","top_or_hot":-1,"title":"BRIEF-Allakos Says AK006 Well-Tolerated In Ongoing Phase 1 Trial","media":"Reuters","content":"<html><body><p>June 25 (Reuters) - Allakos Inc   :</p><p>   * ALLAKOS ANNOUNCES POSITIVE RESULTS FROM ITS ONGOING PHASE 1 TRIAL OF AK006 IN HEALTHY VOLUNTEERS, WITH AK006 DEMONSTRATING HIGH RECEPTOR OCCUPANCY ON MAST CELLS AND A FAVORABLE SAFETY PROFILE</p><p>   * ALLAKOS INC: AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE</p><p>   * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE -</p><p>   * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE</p><p>   * ALLAKOS INC - AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH LEVELS DEMONSTRATING INHIBITORY ACTIVITY IN PRECLINICAL EXPERIMENTS</p><p>   * ALLAKOS INC - AK006 SHOWED DOSE LINEAR EXPOSURE AND WITH AN ESTIMATED HALF-LIFE OF 21 DAYS FOR 720 MG IV DOSE</p><p>   * ALLAKOS-  IN PHASE 1 STUDY RESULTS AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH THOSE SHOWING MAST CELL INHIBITION IN PRECLINICAL EXPERIMENTS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Allakos Says AK006 Well-Tolerated In Ongoing Phase 1 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Allakos Says AK006 Well-Tolerated In Ongoing Phase 1 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-26 04:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>June 25 (Reuters) - Allakos Inc   :   * ALLAKOS ANNOUNCES POSITIVE RESULTS FROM ITS ONGOING PHASE 1 TRIAL OF AK006 IN HEALTHY VOLUNTEERS, WITH AK006 DEMONSTRATING HIGH RECEPTOR OCCUPANCY ON MAST CELLS...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALLK","symbol_name":"Allakos Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2446187991","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446187991","pubTimestamp":1719347087,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"June 25  - Allakos Inc   :   * ALLAKOS ANNOUNCES POSITIVE RESULTS FROM ITS ONGOING PHASE 1 TRIAL OF AK006 IN HEALTHY VOLUNTEERS, WITH AK006 DEMONSTRATING HIGH RECEPTOR OCCUPANCY ON MAST CELLS AND A FAVORABLE SAFETY PROFILE   * ALLAKOS INC: AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE   * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE -   * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE   * ALLAKOS INC - AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH LEVELS DEMONSTRATING INHIBITORY ACTIVITY IN PRECLINICAL EXPERIMENTS   * ALLAKOS INC - AK006 SHOWED DOSE LINEAR EXPOSURE AND WITH AN ESTIMATED HALF-LIFE OF 21 DAYS FOR 720 MG IV DOSE   * ALLAKOS-  IN PHASE 1 STUDY RESULTS AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH THOSE SHOWING MAST CELL INHIBITION IN PRECLINICAL EXPERIMENTSSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"ALLK":"Allakos Inc."},"translate_title":"简介-Allakos表示AK006在正在进行的1期试验中耐受性良好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLK":0.9},"content_text":"June 25 (Reuters) - Allakos Inc   :   * ALLAKOS ANNOUNCES POSITIVE RESULTS FROM ITS ONGOING PHASE 1 TRIAL OF AK006 IN HEALTHY VOLUNTEERS, WITH AK006 DEMONSTRATING HIGH RECEPTOR OCCUPANCY ON MAST CELLS AND A FAVORABLE SAFETY PROFILE   * ALLAKOS INC: AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE   * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE -   * ALLAKOS INC - AK006 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE   * ALLAKOS INC - AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH LEVELS DEMONSTRATING INHIBITORY ACTIVITY IN PRECLINICAL EXPERIMENTS   * ALLAKOS INC - AK006 SHOWED DOSE LINEAR EXPOSURE AND WITH AN ESTIMATED HALF-LIFE OF 21 DAYS FOR 720 MG IV DOSE   * ALLAKOS-  IN PHASE 1 STUDY RESULTS AK006 ACHIEVED SERUM CONCENTRATIONS CONSISTENT WITH THOSE SHOWING MAST CELL INHIBITION IN PRECLINICAL EXPERIMENTSSource text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446187991"}